Drugs / Allogeneic CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07129642 | Aug 2025 → Dec 2026 expected | Graves disease | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07129642 ↗ |
| Modality | Cell therapy | “Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease” NCT07129642 ↗ |
| Target | CD19 | “anti-CD19 CAR-T” NCT07129642 ↗ |